Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients
1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy, associated with improvements...